We advised BrainAurora on its IPO and HKEX listing

Davis Polk advised BrainAurora Medical Technology Limited in connection with its initial public offering and listing on the Hong Kong Stock Exchange and its international offering pursuant to Regulation S. The gross proceeds of the offering were approximately HK$583.18 million.

BrainAurora is a seasoned player in China’s cognitive impairment digital therapeutics (DTx) market. It is the first company in China that has developed a medical-grade DTx product for cognitive impairment, combining brain science with advanced artificial intelligence technologies. BrainAurora’s product pipeline covers both the assessment and intervention of a broad range of cognitive impairments induced by vascular diseases, neurodegenerative diseases, psychiatric disorders and child development deficiencies, among others.

The Davis Polk corporate team included partners Xuelin (Steve) Wang and Jason Xu, counsel Jennifer Ng and associates Edwin Lee and Yi Kai Sit. Counsel Alon Gurfinkel and associates Kelli A. Rivers and Ya Sheng Lin provided tax advice. Counsel Sarah E. Kim provided Investment Company Act of 1940 advice.. Members of the Davis Polk team are based in the Hong Kong, Beijing, London and New York offices.